ROS1 and non-small cell lung carcinoma: While we need to conduct well-designed randomized trials to assess broader efficacy of personalized medicine and validate the bio-markers, we can also enjoy the tremendous success of KIT mutations in gastrointestinal stromal tumor (GIST), BRAF (V600E) in melanoma, EGFR, ALK, and ROS1 alterations in NSCLC [34,35,36].